New Study Results Find That The Blood Biomarker MR-proADM May Prevent Early Hospital Discharge in Patients with Developing Sepsis

by /

New Study Results Find That The Blood Biomarker MR-proADM May Prevent Early Hospital Discharge in Patients with Developing Sepsis

Multi-centre analysis shows that incorporation of MR-proADM (mid-regional proadrenomedullin) into an early management of patients with suspected infection protocol may aid rapid clinical decision making in the emergency department

HENNIGSDORF, Germany, May 2, 2019 /PRNewswire/ — Results from the multi-centre study titled “The early identification of disease progression in patients with suspected infection presenting to the emergency department” have been published in the February issue of Critical Care. In this study, the testing 1175 patients presenting to six European emergency departments (ED) with an initial diagnosis of infection were prospectively enrolled and validated by a secondary analysis of 896 patients with suspected infection from previously published multi-centre study1.

The inappropriate discharge of patients in the early stages of sepsis development is a serious, life-threatening consequence of the complex pathophysiological signs of infection. Indeed, all infections have the potential to manifest into life-threatening conditions, depending on the virulence of the infecting organism and the subsequent pathophysiological host response. Despite a high emphasis being placed on an early identification of patients with sepsis within the ED, failure to identify those with initially low severities, but a high potential for subsequent disease development and progression towards sepsis may lead to either a delayed therapeutic response or inappropriate discharge decisions.

“In our study the biomarker MR-proADM was found to most accurately identify the patients with a high likelihood of further disease progression, compared to all other biomarkers and clinical scores. Incorporation of MR-proADM in an early sepsis management protocol may aid early decision-making in the ED in order to initiate, escalate or intensify further treatment strategies,” said Dr. Kordo Saeed, consultant clinical microbiologist at Hampshire Hospitals NHS Foundation Trust in Winchester and Basingstoke (UK). “Conversely, MR-proADM could also accurately identify patients with low severity, uncomplicated infections, potentially allowing a safer discharge and out-patient management, lowering readmission rates.”

Increased levels of Adrenomedullin (ADM) are generated in disease conditions in order to stabilize the microcirculation and protect against vascular permeability2. However, the reliable measurement of ADM is complicated by its short half-life and rapid degradation. The stable fragment of the peptide, MR-proADM, allows the accurate quantification of incremental changes over the course of therapy. Recent evidence highlights the use of MR-proADM as a highly sensitive biomarker to assess disease severity in patients with sepsis3,4, with concentrations rapidly induced in the initial stages of sepsis development following burns5 and neurological disorders6, as well as in response to invasive fungal infections in septic shock patients7.

For more information, please see the following site: thermoscientific.com/proadrenomedullin

B·R·A·H·M·S MR-proADM KRYPTOR is CE marked but not 510(k)-cleared and not available for sale in the U.S. Availability of product in each country depends on local regulatory marketing authorization status.

About Thermo Fisher Scientific
 Thermo Fisher Scientific Inc. is the world leader in serving science, with revenues of more than $24 billion and approximately 70,000 employees globally. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics, deliver medicines to market and increase laboratory productivity. Through our premier brands – Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services – we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive services. For more information, please visit www.thermofisher.com.

References

  1. Schuetz P, Hausfater P, et al. Biomarkers from distinct biological pathways improve early risk stratification in medical emergency patients: the multinational, prospective, observational TRIAGE study. Critical Care2015; 19:377.
  2. Xie Z, Chen WS, Yin Y, et al. Adrenomedullin surges are linked to acute episodes of the systemic capillary leak syndrome (Clarkson disease). J Leukoc Biol. 2018.
  3. Andaluz-Ojeda D, Nguyen HB, Meunier-Beillard N, et al. Superior accuracy of mid-regional proadrenomedullin for mortality prediction in sepsis with varying levels of illness severity. Ann Intensive Care. 2017;7(1):15. 
  4. Bernal-Morell E, Garcia-Villalba E, Vera MDC, et al. Usefulness of midregional pro-adrenomedullin as a marker of organ damage and predictor of mortality in patients with sepsis. J Infect. 2017.          
  5. Gille J, Ostermann H, Dragu A, Sablotzki A. MR-proADM: A New Biomarker for Early Diagnosis of Sepsis in Burned Patients. J Burn Care Res. 2017;38(5):290-298.   
  6. Bustamante A, Garcia-Berrocoso T, Penalba A, et al. Sepsis biomarkers reprofiling to predict stroke-associated infections. J Neuroimmunol. 2017;312:19-23.
  7. Decker SO, Sigl A, Grumaz C, et al. Immune-Response Patterns and Next Generation Sequencing Diagnostics for the Detection of Mycoses in Patients with Septic Shock-Results of a Combined Clinical and Experimental Investigation. Int J Mol Sci. 2017;18(8).

Contact Information: Dr. Rita Baxmann
Phone: +49 3302 883 303
E-mail: rita.baxmann@thermofisher.com

Logo – https://mma.prnewswire.com/media/490330/Thermo_Fisher_Scientific.jpg

Related News: